Mode
Text Size
Log in / Sign up
Phase 3 N=955 Treatment

Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial

Breast Augmentation · Breast Reconstruction · Breast Revision

Enrolled (actual)
955
Serious AEs
2.0%
Results posted
Apr 2016
Primary outcome: Primary: 10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation — 22.3; 52.7; 35.0; 59.7 percentage of subjects

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Mentor Siltex® Contour Profile Gel Mammary Prosthesis (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Mentor Worldwide, LLC
Primary completion
Oct 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation
22.3; 52.7; 35.0; 59.7
PRIMARY
10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Baker III, IV Capsular Contracture
3.6; 14.3; 15.5; 16.4
PRIMARY
10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Infection
0.7; 1.6; 1.9; 2.9
PRIMARY
10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Explantation With or Without Replacement
9.2; 34.1; 25.9; 49.0
PRIMARY
Overall Mean Change in Circumferential Chest Size
2.1; 0.3; 0.6; 0.1

Summary

The Contour Profile Gel Study is designed to demonstrate safety and effectiveness of Mentor's Mammary Prostheses in women who are undergoing primary augmentation, primary reconstruction, or revision. Safety information on the rate of capsular contracture, rupture, and infection will be collected, and used to help determine device safety. Approximately 1000 patients at approximately 60 medical centers across the United States were enrolled in this research study. These patients were implanted with silicone breast prostheses and will be monitored for 10 years to collect information on risks associated with the implant surgery as well as changes in the way these patients feel about themselves.

Eligibility Criteria

Inclusion Criteria

  • Subject is genetic female, 18 years of age or older
  • A candidate for:
  • Primary breast augmentation (general breast enlargement)
  • Primary breast reconstruction (for trauma, loss of breast tissue due to mastectomy, malignancy, contralateral post-reconstruction symmetry, congenital deformity, including asymmetry)
  • Revision surgery (previous augmentation or reconstruction with silicone-filled or saline-filled implants)
  • Signs the Informed Consent
  • Agrees to return device to Mentor if explant necessary
  • Agrees to comply with follow-up procedures, including returning for all follow-up visits

Exclusion Criteria

  • Subject is pregnant
  • Has nursed a child within three months of study enrollment
  • Been implanted with any silicone implant other than breast implants (e.g. silicone artificial joints or facial implants)
  • Confirmed diagnosis of the following rheumatic diseases or syndromes: SLE, Sjogren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia, or chronic fatigue syndrome
  • Currently has a condition that could compromise or complicate wound healing (except reconstruction subjects)
  • Subject in Augmentation cohort and has diagnosis of active cancer of any type. (Exception is low-grade non-metastasizing skin cancer)
  • Infection or abscess anywhere in the body
  • Demonstrates tissue characteristics which are clinically incompatible with implant (e.g. tissue damage resulting from radiation, inadequate tissue, or compromised vascularity)
  • Possesses any condition, or is under treatment for any condition which, in the opinion of the investigator and/or consulting physicians(s), may constitute an unwarranted surgical risk
  • Anatomic or physiologic abnormality which could lead to significant postoperative adverse events
  • Demonstrates characteristics that are unrealistic/unreasonable with the risks involved with the surgical procedure
  • Premalignant breast disease without a subcutaneous mastectomy
  • Untreated or inappropriately treated breast malignancy, without mastectomy
  • Are HIV positive
  • Work for Mentor or the study doctor or are directly-related to anyone that works for Mentor or the study doctor
  • Implanted metal or metal devices, history of claustrophobia or other condition that would make a MRI scan prohibitive
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00812097). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search